ABSTRACT

People suffering from diabetes are not able to produce enough insulin and/or properly use it in the body, thus they have a high level of blood glucose. It is associated with decreased insulin secretion, increased peripheral (muscle, fat, liver) insulin resistance. It has been observed that treatment of type II diabetes is generally focused on the control of hyperglycemia even though 80% of diabetic patients die from macrovascular complications of the disease. Arylidene-2,4 thiazolidinedione structure is common in a variety of agents, however they differ in side chain modifications which influence their pharmacological actions. Synthesis of arylidene-2,4- thiazolidinedione generally involves reaction between chloroacetic acid and thiourea to form 2,4- thiazolidinedione followed by base mediated substitution at nitrogen and condensation reaction at methylene carbon. Arylidene-2,4 thiazolidinedione as aldose reductase inhibitor prevent or slow the action of aldose reductase leading to prevention or delay of complications of diabetes. Arylidene-2,4 thiazolidinedione has been evaluated as inhibitors of protein tyrosine phosphatases 1B. Investigation of antidiabetic activity of series of 2,4-thiazolidinedione derivatives for their loss of plasma glucose lowering activity has been performed. Keywords: Diabetes, Arylidene-2,4 thiazolidinedione, Aldose reductase inhibitor, Protein tyrosine phosphatase 1B inhibitor, Antihyperglycemic agents
Publication date: 01/09/2024

https://ijbpas.com/pdf/2024/September/MS_IJBPAS_2024_8294.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.9.8294